MedPath

Nordic MDS Group

Sweden
Ownership
Private
Established
1984-01-01
Employees
-
Market Cap
-
Website
http://www.nmds.org/

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Conditions
MRD
SCT
MDS
First Posted Date
2016-08-19
Last Posted Date
2018-01-30
Lead Sponsor
Nordic MDS Group
Target Recruit Count
200
Registration Number
NCT02872662
Locations
🇳🇴

Department of Medcine, Haukeland University Hospital, Bergen, Norway

🇸🇪

Department of Hematology, Lund University Hospital, Lund, Sweden

🇩🇰

Department of Hematology, Rigshospitalet Univsersity Hospital, Copenhagen, Denmark

and more 5 locations

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Phase 2
Conditions
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Interventions
First Posted Date
2012-03-16
Last Posted Date
2012-03-16
Lead Sponsor
Nordic MDS Group
Target Recruit Count
72
Registration Number
NCT01556477
Locations
🇸🇪

Lars Möllgård, Stockholm, Sweden

Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)

Phase 1
Completed
Conditions
Myelodysplastic Syndrome
Thrombocytopenia
Interventions
First Posted Date
2011-11-29
Last Posted Date
2013-05-03
Lead Sponsor
Nordic MDS Group
Target Recruit Count
12
Registration Number
NCT01481220
Locations
🇸🇪

4 Locations, Uppsala, Stockholm, Göteborg, Umeå, Sweden

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Phase 2
Completed
Conditions
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Interventions
Drug: Azacitidine
Drug: Erythropoetin
First Posted Date
2010-01-13
Last Posted Date
2013-10-29
Lead Sponsor
Nordic MDS Group
Target Recruit Count
30
Registration Number
NCT01048034
Locations
🇩🇰

Department of Hematology, Aarhus Univsersity Hospital, Aarhus, Denmark

🇸🇪

Department of Hematology, Linköping University Hospital, Linköping, Sweden

🇸🇪

Department of medicine, Falun Hospital, Falun, Sweden

and more 14 locations

Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5

Phase 2
Completed
Conditions
MDS
AML
Interventions
First Posted Date
2008-09-29
Last Posted Date
2012-04-27
Lead Sponsor
Nordic MDS Group
Target Recruit Count
28
Registration Number
NCT00761449
Locations
🇩🇰

Department of Hematology, Aalborg Hospital, Aalborg, Denmark

🇩🇰

Department of Hematology, Herlev Hospital, Herlev, Denmark

🇩🇰

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

and more 15 locations
© Copyright 2025. All Rights Reserved by MedPath